Report Details

Pre-filled syringes and related devices - discover companies' revenue prospects

How are companies in the pre-filled syringe industry performing? Visiongain's report gives you data, analyses and discussions for producers of those drug delivery devices.

Our updated study lets you assess leading companies in the pre-filled (ready-to-fill) syringe industry and market, showing you their prospects to 2023. There you see financial results, interviews, trends, opportunities and revenue predictions.

That way, you discover information you need on established and emerging companies. Read on to scan those organisations and see what their future market could be worth.

See forecasts and discussions to help you stay ahead in knowledge

In our study you find analytical profiles of 15 top companies - and analyses of the overall industry - with historical data, revenue forecasts and growth rates. You also see qualitative analysis, business outlooks and developments. You gain 80 tables and 32 charts.

Our work lets you assess the most lucrative areas of those drug delivery technologies, seeing opportunities both for makers of drugs and of those medical injection devices.

That way you can stay ahead in knowledge of the industry and market for these medical devices:
• Plastic syringes
• Glass syringes
• Related injection products and disposable (single-use) systems for injecting drugs.

The following sections highlight what you find in our new study.

What you discover in our company profiles

Our report profiles 15 leading companies across four sectors of the pre-filled injection devices market. The content of each profile differs, depending on the company. In general, however, a profile contains the following information:
• Overview of the company, including its history in the pre-filled injection device market
• Discussions of the company's pre-filled injection device product/service portfolio, including an identification of main clients
• Analysis of the company's recent financial performance, for overall revenue and, where possible, pre-filled injection device revenue
• Assessment of its recent developments in the pre-filled injection device market, e.g. acquisitions, facility expansions, product launches and collaborations with the pharmaceutical industry
• Qualitative analysis of the company, identifying strengths over its competitors, as well as its opportunities for sales growth
• Prediction of revenue for the period 2013-2023 (for 10 of the 15 companies).

Also, in 2012 and 2013, visiongain interviewed five of the 15 profiled companies. Those surveys cover how product and service demand for the companies has changed in recent years, as well as how that demand can change in coming years.

Those interviews include views on the development of the pre-filled syringe market. Our study also shows comparison and analysis of those interviews, summarising their lessons.

See prospects for leading pre-filled syringe manufacturers

Our study gives you discussions and financial analyses for leading producers of pre-filled syringes:
• Becton, Dickinson & Co. (BD)
• Gerresheimer
• Schott
• Nipro
• Nuova Ompi.

Discover what the future holds for those pharma-related medical device companies, seeing how they compare and compete. You see where the best prospects exist.

Suppliers and users of pre-filled injection systems will benefit from 2013 onwards. Next, our investigation analyses developers and producers of associated technologies.

What's the outlook for manufacturers of pre-filled syringe components?

Our report shows you developments and revenue prospects for leading producers of syringe components:
• Aptar Stelmi
• Datwyler Holding
• West Pharmaceutical Services.

There you see opportunities for companies making plungers, needle shields, tip caps and related products.

Our work shows you where sales growth can occur. Many opportunities remain, with expanding revenues possible from 2013 to 2023.

Find prospects for leading pen injector and autoinjector producers

In our study you also see commercial outlooks for top manufacturers of pen injectors and autoinjectors:
• Haselmeier
• Owen Mumford
• SHL Group
• Ypsomed.

There you assess product portfolios, strategies and revenue prospects. You also investigate associated organisations and competition. Our work shows you possibilities for advancing technology and raising sales.

Who are the leading pre-filled syringe contract manufacturers?

Our work assesses contract manufacturing organisations (CMOs) in that field. There you discover activities of these prominent organisations:
• Catalent
• Hospira One2One
• Vetter Pharma.

There you also assess the competitive outlook for leading CMOs in that market. You also see discussions of biological drugs (biologics), lyophilisation and dual-chamber syringes.

Where is that overall area of drug delivery heading?

Our analysis predicts overall world revenues for those pre-filled injection devices - the drug delivery technology - will reach $4.47bn in 2017. These will expand further to 2023.

Greater use of biologics and vaccines will raise demand for parenteral delivery systems. Many opportunities exist, especially for plastic syringes and ready-to-use containment of labile drugs and other complex pharmaceuticals. Our study explains.

What about applications? The incidence of diabetes and expansion of the home healthcare market, in particular, will stimulate demand for pre-filled drug injection systems.

What about market needs? Medical injection systems giving improved clinical efficacy, safety and convenience will achieve commercial success this decade, our analyses show. See, then, prospects from 2013 to 2023 for that market and its leading companies.

Seven ways Pharma Leader Series: Top Pre-Filled Injection Device Manufacturers 2013-2023 helps you

To sum up then, our investigation gives you the following knowledge:
• Revenues to 2023 for the overall world market and two product categories - you discover that industry's prospects, finding lucrative areas for investments and revenues
• Profiles of 15 leading companies - you assess products, services, sales results and outlooks, also gaining 10 revenue forecasts to 2023
• Interviews with 5 top companies in the industry - you discover debates and opinions to help you stay ahead
• Competition and opportunities - you see what affects that industry and shapes its future, especially needs for injecting biologics, biosimilars and other viscous drugs
• Discussions of technological progress and market expansion - you investigate developments, exploring possibilities for technological and commercial advances
• Analysis of what stimulates and restrains that industry and market - you assess challenges and strengths, helping you compete and gain advantages
• Prospects for established competitors and firms seeking to enter the sector - you explore needs, practices and outlooks for future success.

You gain information found nowhere else

That work gives independent analysis. There you receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.

Discover prospects for leading drug injection device companies by ordering now

Our investigation is for everyone needing analysis of the industry and market for drug delivery via injections. There you find data, trends, opportunities and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table Of Contents

Table of Contents

1. Executive Summary
1.1 Outlook for the Leading Pre-Filled Injection Device Manufacturers 2013-2023
1.2 Reports Contents
1.2.1 Company Profile Contents
1.3 Research Analysis and Methods
1.3.1 Terminology Used in the Report

2. Introduction to the Pre-Filled Injection Device Market
2.1 A Brief History of Syringes and Pre-Filled Injection Systems
2.2 Components of Pre-Filled Syringes
2.2.1 Glass vs. Plastic Syringes
2.2.2 Pen Injectors and Autoinjectors
2.2.3 Benefits and Weaknesses of Pre-Filled Injection Devices
2.3 The Pre-Filled Injection Device Market 2013-2023
2.3.1 A Rapidly Growing Market 2011-2012
2.3.2 Contract Manufacturing as a Sector of the Pre-Filled Syringe Market
2.3.3 Demand is Greatest in Developed Countries
2.3.4 Pre-Filled Syringe Market Forecast 2013-2023
2.4 Key Trends in the Pre-Filled Injection Device Market 2013-2023
2.4.1 Increased Market Consolidation
2.4.2 Increased Development of Biologics and Biosimilars
2.4.3 The Rise in At-Home Care
2.4.4 Greater Demands for Safety Leading Innovation
2.4.5 The Threat from Other Drug Delivery Technologies

3. Leading Pre-Filled Syringe Manufacturers 2013-2023
3.1 Becton, Dickinson and Co. (BD)
3.1.1 BD Has a Broad Pre-Filled Syringe Product Range
3.1.1.1 BD Hypak: The World's First Glass Pre-Filled Syringe
3.1.1.2 BD Sterifill
3.1.1.3 BD Soluvia
3.1.1.4 Uniject is a Product for Emerging Markets
3.1.1.5 BD Physioject: BD's Autoinjector
3.1.1.6 BD Markets Pen Injectors for Lyophilised Drugs
3.1.1.7 BD's Proprietary Syringe Safety Systems
3.1.2 Steady Growth for BD's Pre-Filled Injection Device Revenue 2011-2012
3.1.3 BD Acquires Safety Syringes
3.1.4 Many New Product Launches Planned
3.1.4.1 BD Vystra Disposable Pen is the Company's Latest Pre-Filled Injection System
3.1.5 What Opportunities Are There for BD in this Market?
3.1.5.1 BD Will Continue to Expand
3.1.6 BD Pharmaceutical Systems: Revenue Forecast 2013-2023
3.2 Gerresheimer
3.2.1 Gerresheimer's Pre-Filled Syringe Products
3.2.1.1 Ready-To-Fill (RTF) Syringes
3.2.1.2 Gerresheimer Licensed Polymer Syringes from Taisei Kako
3.2.1.3 Gerresheimer Began Manufacturing Pen Injectors in 2009
3.2.2 Strong Revenue Growth for Gerresheimer 2010-2012
3.2.3 Rapid Growth in the Plastic Systems Division
3.2.3.1 Gerresheimer Expands in India
3.2.4 RTF Expansion Has Been More Steady
3.2.5 Gerresheimer: SWOT Analysis 2013-2023
3.2.5.1 Rapid Growth Planned for Emerging Markets
3.2.5.2 Gerresheimer is Well Placed for Biologics Growth
3.2.6 Growing Market Share for Gerresheimer's Pen Injectors?
3.3 Schott
3.3.1 Schott Markets Glass and Plastic Pre-Filled Syringes
3.3.1.1 Forma 3s Glass Syringes
3.3.1.2 TopPac Polymer Syringes
3.3.1.3 InJentle Syringes for Sensitive Drug Products
3.3.2 Schott: Financial Performance 2008-2011
3.3.3 Expansion in Developed and Emerging Markets
3.3.3.1 Growth in India, Russia and China
3.3.4 Schott Is Well-Placed for Growing Biologics Demand
3.3.4.1 Becoming a Leader in Russia
3.3.5 Schott: Expert Opinion on the Pre-Filled Injection Device Market
3.4 Nipro: A Market Leader Through its MGlas Acquisition
3.4.1 Pre-Filled Syringe Product Overview
3.4.2 Nipro is Expanding Globally
3.4.3 Nipro: SWOT Analysis 2013-2023
3.4.3.1 Responding to Rising Diabetes Incidence
3.5 Nuova Ompi: A Glass Manufacturing Specialist
3.5.1 Nuova Markets Glass Pre-Filled Syringes and Cartridges
3.5.1.1 EZ-Fill Syringes
3.5.1.2 Extra High Quality (XQ) Syringes
3.5.2 Focused on Growth for Cartridges and Vials Manufacturing in Emerging Markets
3.5.3 Nuova Ompi Offers Customised Manufacturing Solutions
3.5.3.1 Nuova's Products for the Biologics Market
3.5.3.2 Significant Investment Planned to 2016
3.5.4 Nuova Ompi: Company Insight
3.6 Pre-Filled Syringe Manufacturers: Competitor Analysis 2013-2023
3.6.1 The Need for Advanced Safety Systems
3.6.2 Meeting the Demands of Biologic and Biosimilar Developers
3.6.3 Product Portfolio Diversity
3.6.4 What Demand is there in Emerging Markets?
3.7 High Barriers to Market Entry Will Limit Competition to 2023
3.7.1 Unilife Manufactures Novel Pre-Filled Injection Systems
3.7.2 Revolutions Medical: A Disposable Syringe Manufacturer Entering the Pre-Filled Market

4. Leading Pre-Filled Syringe Component Manufacturers 2013-2023
4.1 Aptar Stelmi is a Pharma Packaging Specialist
4.1.1 Aptar Stelmi's Pre-Filled Syringe Components
4.1.1.1 Stelmi's Rigid Needle Shields
4.1.2 Aptar Has Access to the Autoinjector Market Through Oval Medical
4.1.3 Aptar Stelmi's Revenue Grows Over 10% Annually 2004-2012
4.1.4 Aptar Stelmi: SWOT Analysis 2013-2023
4.1.4.1 Regional Expansion is Important for Continued Growth
4.1.5 Continued Revenue Growth for Aptar Stelmi 2013-2023
4.2 Datwyler Holding
4.2.1 Datwyler's Pre-Filled Syringe Components
4.2.1.1 Omniflex Coating: An Alternative to Silicone Oil
4.2.2 Demand from Insulin Manufacturers Drives Revenue Growth 2007-2012
4.2.3 Datwyler Is Focused on High-Value Expansion
4.2.4 Growth in Emerging Markets
4.2.5 Datwyler: SWOT Analysis
4.2.6 What Will Drive Growth for Datwyler Pharma Packaging to 2023?
4.2.7 Datwyler: Pre-Filled Injection Device Market Insight
4.3 West Pharmaceutical Services
4.3.1 West Manufactures Syringes and Syringe Components
4.3.1.1 Daikyo Crystal Zenith: Licensed from Daikyo Seiko
4.3.1.2 MixJect for Lyophilised Drugs
4.3.1.3 West's Self-Injection Systems
4.3.1.4 West Markets Three Safety Systems
4.3.2 Recent Financial Performance
4.3.3 Collaborations with Big Pharma for Product Development
4.3.4 West Enters the Indian Market
4.3.5 West: Opportunities for Growth 2013-2023
4.3.6 Pre-Filled Injection Device Revenue Forecast 2013-2023
4.3.7 West Pharmaceutical Services: Company Insight
4.4 Pre-Filled Syringe Component Manufacturers: Competitor Analysis 2013-2023
4.4.1 How Can Component Manufacturers React to Increased Safety Demands?
4.4.1.1 Tip-top Offers Three Safety Products for Pre-Filled Syringes
4.4.1.2 Rexam Receives Approval for its Safe'n'Sound Passive Safety System
4.4.2 Entering the Autoinjector Market
4.4.3 Component Manufacturers Following Pre-Filled Syringe Manufacturers to Emerging Markets

5. Leading Pen Injector and Autoinjector Manufacturers 2013-2023
5.1 Haselmeier
5.1.1 Haselmeier Markets Five Injection Systems
5.1.1.1 Axis Pen Systems
5.1.1.2 i-Pen: Haselmeier's Insulin Pen Injector
5.1.2 Company Growth in Germany and India
5.1.3 Haselmeier: Opportunities for Expansion 2013-2023
5.2 Owen Mumford
5.2.1 Autoinjector and Pen Injector Overview
5.2.1.1 Autoject
5.2.1.2 Autopen
5.2.1.3 SimpleJect: Designed for RA Patients
5.2.2 Recent Financial Performance
5.2.3 Innovative Products to Drive Growth
5.2.4 Expanding in Established and New Markets
5.2.5 Owen Mumford: SWOT Analysis 2013-2023
5.2.6 Owen Mumford: Company Revenue Forecast 2013-2023
5.3 SHL Group
5.3.1 SHL Manufactures a Broad Range of Injection Devices
5.3.1.1 Molly Autoinjector
5.3.1.2 DAI Autoinjectors
5.3.2 SHL Group Continues to Grow in Taiwan
5.3.3 SHL Group: Pen Injector and Autoinjector Market Outlook 2013-2023
5.4 Ypsomed
5.4.1 Product Portfolio
5.4.1.1 YpsoPen
5.4.1.2 ServoPen
5.4.1.3 UnoPen
5.4.1.4 LyoTwist Injectors for Lyophilised Drugs
5.4.1.5 Ypsomed Markets Two Autoinjectors
5.4.2 Ypsomed: Financial Performance 2009-2012
5.4.2.1 Continued Delivery Devices Revenue Decline for FY 2013
5.4.3 A Focus on Diabetes
5.4.4 What Are Ypsomed's Strengths in the Pre-Fill Injection Device Market 2013?
5.4.5 Ypsomed Delivery Devices Revenue Forecast 2013-2023
5.4.6 Ypsomed: Company Insight
5.5 Pen Injector and Autoinjector Manufacturers: Competitor Analysis 2013-2023
5.5.1 A Highly Competitive Market 2013-2023
5.5.2 How Are Companies Differentiating Their Autoinjectors?
5.5.3 Rising Demand in At-Home Care
5.5.3.1 Specific Demands in RA and MS
5.5.4 Contract Manufacturing for Autoinjectors

6. Leading Pre-Filled Syringe Contract Manufacturers 2013-2023
6.1 Catalent is the World's Largest CMO
6.1.1 Pre-Filled Syringe Contract Manufacturing Capabilities
6.1.2 Catalent Offers an Autoinjector
6.1.3 Catalent Pharma Solutions: Financial Performance 2011-2012
6.1.4 Expanding Filling Capacity for Clinical Trial Materials
6.1.5 Catalent: SWOT Analysis 2013-2023
6.1.6 Catalent Pre-Filled Syringe and Cartridge Filling Revenue Forecast 2013-2023
6.2 Hospira One2One
6.2.1 Hospira and the Pre-Filled Injection Device Industry
6.2.1.1 iSecure Syringe: Hospira's Pre-Filled Injection System
6.2.2 Facility Expansion in Emerging Markets
6.2.3 Hospira: Market Outlook 2013-2023
6.2.4 Hospira One2One: Pre-Filled Injection Device Revenue Forecast 2013-2023
6.3 Vetter Pharma
6.3.1 Vetter Is an Injectable Manufacturing Specialist
6.3.2 Vetter Grows in the US and Germany
6.3.3 New Services and Collaborations
6.3.4 Vetter: SWOT Analysis 2013-2023
6.3.5 Outlook for Vetter: Pre-Filled Injection Device Revenue Forecast 2013-2023
6.4 The Competitive Outlook for Leading CMOs in the Market 2013-2023
6.4.1 Biologics, Lyophilisation and Dual-Chamber Syringes
6.4.2 An Increasingly Competitive Market?
6.5 Other Pre-Filled Syringe Contract Manufacturers 2013
6.5.1 ROVI Has the Capacity to be a Market Leader
6.5.1.1 ROVI CM's Pre-Filled Syringe Capabilities
6.5.2 AMRI Entered the Market Through its Acquisition of HCM
6.5.2.1 AMRI's Recent Financial Performance
6.5.3 Boehringer Ingelheim

7. Conclusions from Our Study
7.1 Outlook for the Pre-Filled Injection System Market 2013-2023
7.2 Outlook for Leading Pre-Filled Injection System Manufacturers 2013-2023
7.2.1 How Will the Leading Companies' Revenues Grow to 2023?
7.3 Company Insight Analysis: Common and Different Growth Strategies 2013-2023
7.3.1 How Have Customer Demands Changed in Recent Years?
7.3.1.1 How Will These Demands Change in the Future?
7.3.2 How Important Will Emerging Markets Be in this Decade?
7.4 Concluding Remarks



List of Tables

Table 1.1 Currency Exchange Rates, 2012
Table 2.1 Pre-Filled Injection Device Market, 2011
Table 2.2 Pre-Filled Injection Device Market by Region, 2011
Table 2.3 Pre-Filled Injection Device Market Forecast, 2011, 2017 and 2023
Table 2.4 Pre-Filled Injection Device Market: STEP Analysis, 2013-2023
Table 2.5 Selected Acquisitions in the Pre-Filled Injection Device Market, 2010-2012
Table 3.1 BD: Key Facts, 2013
Table 3.2 BD: Revenue by Division, 2010-2012
Table 3.3 BD Medical: Revenue by Division, 2011-2012
Table 3.4 BD Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 3.5 BD Pharmaceutical Systems: Revenue Forecast, 2012-2023
Table 3.6 Gerresheimer: Employees by Region, 2012
Table 3.7 Gerresheimer: Key Facts, 2013
Table 3.8 Gerresheimer: Revenue by Division, 2010-2012
Table 3.9 Gerresheimer Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 3.10 Gerresheimer Pen Injectors: Revenue Forecast, 2012-2023
Table 3.11 Schott: Key Facts, 2013
Table 3.12 Schott: Revenue, 2008-2011
Table 3.13 Schott Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 3.14 Nipro: Key Facts, 2013
Table 3.15 Nipro Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 3.16 Nuova Ompi: Key Facts, 2013
Table 3.17 Nuova Ompi Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 3.18 Pre-Filled Syringes: Leading Product Comparisons, 2013
Table 3.19 Leading Pre-Filled Syringe Manufacturers: Comparative Product Ranges, 2013
Table 3.20 Unilife: Revenue, 2008-2012
Table 3.21 Revolutions Medical: RevVac Distribution Agreements, 2011-2012
Table 4.1 Aptar Stelmi: Key Facts, 2013
Table 4.2 Aptar Stelmi: Revenue, 1999-2012
Table 4.3 Aptar Stelmi Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 4.4 Aptar Stelmi: Revenue Forecast, 2012-2023
Table 4.5 Datwyler: Key Facts, 2013
Table 4.6 Datwyler: Pharma Packaging Revenue, 2007-2012
Table 4.7 Datwyler Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 4.8 Datwyler Pharma Packaging: Revenue Forecast, 2012-2023
Table 4.9 West: Selected Pharmaceutical Industry Partners, 2013
Table 4.10 West: Key Facts, 2013
Table 4.11 West: Revenue by Division, 2009-2011
Table 4.12 West Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 4.13 West: Pre-Filled Syringe and Device Revenue, 2009-2011
Table 4.14 West Pre-Filled Injection Devices: Revenue Forecast, 2012-2023
Table 5.1 Haselmeier: Key Facts, 2013
Table 5.2 Selected Partners for the i-Pen, 2013
Table 5.3 Haselmeier Injection Devices: SWOT Analysis, 2013-2023
Table 5.4 Owen Mumford: Key Facts, 2013
Table 5.5 Selected Partners for the i-Pen, 2013
Table 5.6 Owen Mumford: Revenue by Region, 2010-2011
Table 5.7 Owen Mumford Injection Devices: SWOT Analysis, 2013-2023
Table 5.8 Chinese Insulin Market by Company, 2012
Table 5.9 Owen Mumford: Revenue Forecast, 2012-2023
Table 5.10 SHL Group: Key Facts, 2013
Table 5.11 SHL Group: Pen Injectors and Autoinjectors, 2013
Table 5.12 SHL Group Injection Devices: SWOT Analysis, 2013-2023
Table 5.13 Ypsomed: Key Facts, 2013
Table 5.14 Ypsomed: Pen Injectors and Autoinjectors, 2013
Table 5.15 Selected Pharmaceutical Partners for Ypsomed's Pen Injectors, 2013
Table 5.16 LyoTwist Injectors Available, 2013
Table 5.17 Ypsomed: Revenue by Division, 2009-2012
Table 5.18 Ypsomed: Revenue by Division, H1 2012-2013
Table 5.19 Ypsomed Injection Devices: SWOT Analysis, 2013-2023
Table 5.20 Ypsomed Delivery Devices: Revenue Forecast, 2012-2023
Table 5.21 Pen Injectors: Product Comparisons, 2013
Table 5.22 Autoinjectors: Product Comparisons, 2013
Table 5.23 Selected Other Pen Injector and Autoinjector Manufacturers, 2013
Table 6.1 Catalent: Employees by Region, 2013
Table 6.2 Catalent: Key Facts, 2013
Table 6.3 Catalent: Revenue by Division, 2011-2012
Table 6.4 Catalent Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 6.5 Catalent Pre-Filled Injection Device Filling: Revenue Forecast, 2012-2023
Table 6.6 Hospira One2One: Key Facts, 2013
Table 6.7 Hospira Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 6.8 Hospira One2One Pre-Filled Injection Device Filling: Revenue Forecast, 2012-2023
Table 6.9 Vetter Pharma: Key Facts, 2013
Table 6.10 Vetter Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 6.11 Vetter Pre-Filled Injection Device Filling: Revenue Forecast, 2012-2023
Table 6.12 Leading Pre-Filled Syringe CMOs: Company Comparison, 2013
Table 7.1 Leading Pre-Filled Injection Device Manufacturers: Revenue Growth, 2012-2023
Table 7.2 Company Insight: Changing Customer Demands
Table 7.3 Company Insight: Pharmaceutical Industry Trends Influencing the Pre-Filled Injection Device Industry
Table 7.4 Company Insight: Future Expectations for Customer Demand, 2013-2023
Table 7.5 Company Insight: Emerging Market Expectations, 2013-2023



List of Figures

Figure 2.1 Pre-Filled Injection Device Market, 2011
Figure 2.2 Pre-Filled Injection Device Market by Region, 2011
Figure 2.3 Pre-Filled Injection Device Market Forecast, 2011, 2017 and 2023
Figure 2.4 Global Diabetes Prevalence, 2000 and 2030
Figure 3.1 BD: History in the Syringe and Pre-Filled Syringe Markets, 1898-2012
Figure 3.2 BD: Revenue by Division, 2010-2012
Figure 3.3 BD Medical: Revenue by Division, 2011-2012
Figure 3.4 BD Pharmaceutical Systems: Revenue Forecast, 2012-2023
Figure 3.5 Gerresheimer: Employees by Region, 2012
Figure 3.6 Gerresheimer: Revenue by Division, 2010-2012
Figure 3.7 Gerresheimer Pen Injectors: Revenue Forecast, 2012-2023
Figure 3.8 Schott: Revenue, 2008-2011
Figure 3.9 Schott Survey Results: Demands from the Market and Future Product Requirements
Figure 3.10 Unilife: Revenue, 2008-2012
Figure 4.1 Aptar Stelmi: Revenue, 1999-2012
Figure 4.2 Aptar Stelmi: Revenue Forecast, 2012-2023
Figure 4.3 Datwyler: Pharma Packaging Revenue, 2007-2012
Figure 4.4 Datwyler Pharma Packaging: Revenue Forecast, 2012-2023
Figure 4.5 West: Revenue by Division, 2009-2011
Figure 4.6 West: Pre-Filled Injection Device Revenue, 2009-2011
Figure 4.7 West Pre-Filled Injection Devices: Revenue Forecast, 2012-2023
Figure 5.1 Owen Mumford: Revenue by Region, 2011
Figure 5.2 Chinese Insulin Market by Company, 2012
Figure 5.3 Owen Mumford: Revenue Forecast, 2012-2023
Figure 5.4 Ypsomed: Revenue by Division, 2009-2012
Figure 5.5 Ypsomed: Revenue by Division, H1 2012-2013
Figure 5.6 Ypsomed Delivery Devices: Revenue Forecast, 2012-2023
Figure 6.1 Catalent: Employees by Region, 2013
Figure 6.2 Catalent: Revenue by Division, 2011-2012
Figure 6.3 Catalent Pre-Filled Injection Device Filling: Revenue Forecast, 2012-2023
Figure 6.4 Hospira One2One Pre-Filled Injection Device Filling: Revenue Forecast, 2012-2023
Figure 6.5 Vetter Pre-Filled Injection Device Filling: Revenue Forecast, 2012-2023



Companies Listed

AbbVie
Actavis (formerly Watson Pharmaceuticals)
Amcor Glass Tubing (part of Nipro)
American Stelmi (part of Aptar Stelmi)
Amgen
Albany Molecular Research (AMRI)
Amylin Pharmaceuticals
Antares Pharma
Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
Aptar Stelmi (part of Aptargroup)
AptarGroup
AstraZeneca
B. Braun Medical
Baxter BioPharma Solutions (part of Baxter)
Baxter International
Bayer
BD Medico
Becton, Dickinson and Co. (BD)
Berlin-Chemie (part of Menarini Group)
Bespak Injectables
Biocon
Biogen Idec
Bionime
Blackstone Group
Boehringer Ingelheim
Boehringer Ingelheim BioXcellence
Bristol-Myers Squibb
Cambridge Consultants
Cardinal Health
Cardium Therapeutics
Carl Zeiss Foundation
Carmel Pharma
Catalent Pharma Solutions
CeifiT
Centers for Disease Control and Prevention (CDC) [US]
Daikyo Seiko
Datwyler Holding
Debiopharm Group
Diagenode
Disetronic Group (part of Roche)
Dong-A Pharmaceutical
DS WorldMed
Duoject
DuPont
Elcam Medical
Eli Lilly
European Commission
European Medicines Agency (EMA)
Ferring Pharmaceuticals
Food and Drug Administration (FDA) [US]
Future Injection Technologies
Genentech (part of Roche)
Gerresheimer
Gerresheimer item (part of Gerresheimer)
GSK
Haselmeier
Hospira
Hospira One2One (part of Hospira)
Hyaluron Contract Manufacturing (HCM, part of AMRI)
Incepta Pharmaceuticals
Insulet
JandJ
Jabil Circuit
Janssen Biotech (part of JandJ)
Korea Food and Drug Administration (KFDA)
Laboratorios Farmaceuticos ROVI
LifeScan
McKesson
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Medimop Medical Projects (part of West Pharmaceutical Services)
Menarini Group
Merck and Co.
Merck KGaA
MG Sterile Products (part of Nipro)
MGlas (part of Nipro)
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Neutral Glass and Allied Industries
Nipro
Nipro Europe (part of Nipro)
Nipro Glass (part of Nipro)
Nipro Medical (part of Nipro)
Novartis
Novo Nordisk
Nuova Ompi (part of Stevanato Group)
Nycomed (part of Takeda)
Nypro
Occupational Safety and Health Administration (OSHA) [US]
Ompi of America (part of Stevanato Group)
Optrel (part of Stevanato Group)
Oval Medical
Owen Mumford
PA Consulting Group
PATH
Pema Holding
Pfizer
Pharma-Pen (part of West Pharmaceutical Services)
Pharmstandard
Phillips Medisize
Plastef Investissements
Polfa-Tarchomin
Primequal
Revolutions Medical
Rexam
Roche
ROVI CM (part of Laboratorios Farmaceuticos ROVI)
Safety Syringes (part of BD)
Sandoz (part of Novartis)
Sanex Packaging Connections
Sanofi
Sanofi Pasteur
Savient Pharmaceuticals
Schering-Plough (part of Merck and Co.)
Schott
Schott Kaisha
Sentry BioPharma Services
Shanghai Fosun Pharmaceutical
SHL Group
Spami (part of Stevanato Group)
Square Pharmaceuticals
Stallergenes
Stelmi Asia (part of Aptar Stelmi)
Stevanato Group
Sungwon Medical
Swedish Orphan Biovitrum (Sobi)
Taisei Kako
Teva Pharmaceutical Industries
The Tech Group (part of West Pharmaceutical Services)
tip-top
Tissue Repair Company (part of Cardium Therapeutics)
Tolmar
Tonghua Dongbao Pharmaceutical
Triveni Polymers
UCB
Unilife
US Agency for International Development
Vetter Pharma
West Company Mexico
West Pharmaceutical India Packaging Private (part of West Pharmaceutical Services)
West Pharmaceutical Services
Wockhardt
World Health Organization (WHO)
Ypsomed
Zeon Corporation

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Global Wound Care Market Outlook

Global Wound Care Market Outlook

  • $ 8 000
  • Industry report
  • October 2014
  • by Frost & Sullivan

Analysis of Wound Care Technologies The global wound care market is at a growth stage. It is driven by the increasingly aging population as well as rising rates of diabetes and obesity. These chronic health ...

World Medical Disposables Market

World Medical Disposables Market

  • $ 6 400
  • Industry report
  • September 2014
  • by Freedonia

World medical disposables demand to increase 6.6% annually through 2018 The Freedonia Group projects that world demand for disposable medical supplies will increase 6.6 percent yearly to nearly $245 billion ...

Global Advanced Wound Care Market 2014-2018

Global Advanced Wound Care Market 2014-2018

  • $ 2 500
  • Industry report
  • September 2014
  • by Infiniti Research Limited

About Wounds A wound is described as a disruption in the integrity of the skin, mucous membrane, or organ tissue. Wounds are caused by mechanical, chemical, thermal, and radiogenic trauma. Wound also occurs ...

Wound Healing Partnering 2009-2014

November 2014 $ 1 795

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.